Immuneering Corporation (IMRX) is experiencing a significant surge in its stock price, up 18.63% to $2.37 as of 1:41 pm on October 15, following the announcement that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug IMM-1-104 for the treatment of pancreatic cancer. The stock opened at $2.46 and has seen a high of $2.51 and a low of $2.15 today. The trading volume has reached an extraordinary 24,264,368 shares, which is 383.94% of its average daily volume of 6,319,768, indicating intense trading activity. The orphan drug designation provides several benefits, including potential tax credits and exemptions from certain FDA fees, which could significantly support Immuneering's research and development efforts.